The Critical Choice of Animal Models in Nanomedicine Safety Assessment: A Lesson Learned From Hemoglobin-Based Oxygen Carriers

Peter Bedőcs1,2,3 and János Szebeni4,5,6*

1 Department of Anesthesiology, Uniformed Services University of the Health Sciences, Bethesda, MD, United States, 2 Henry M Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, United States, 3 Defense and Veterans Center for Integrative Pain Management, Rockville, MD, United States, 4 Nanomedicine Research and Education Center, Department of Translational Medicine, Semmelweis University, Budapest, Hungary, 5 SeroScience Ltd., Budapest, Hungary, 6 Department of Nanobiotechnology and Regenerative Medicine, Faculty of Health, University of Miskolc, Miskolc, Hungary

Intravenous injection of nanopharmaceuticals can induce severe hypersensitivity reactions (HSRs) resulting in anaphylactoid shock in a small percentage of patients, a phenomenon explicitly reproducible in pigs. However, there is a debate in the literature on whether the pig model of HSRs can be used as a safety test for the prediction of severe adverse reactions in humans. Given the importance of using appropriate animal models for toxicity/safety testing, the choice of the right species and model is a critical decision. In order to facilitate the decision process and to expand the relevant information regarding the pig or no pig dilemma, this review examines an ill-fated clinical development program conducted by Baxter Corporation in the United States 24 years ago, when HemeAssist, an αα (diaspirin) crosslinked hemoglobin-based O2 carrier (HBOC) was tested in trauma patients. The study showed increased mortality in the treatment group relative to controls and had to be stopped. This disappointing result had far-reaching consequences and contributed to the setback in blood substitute research ever since. Importantly, the increased mortality of trauma patients was predicted in pig experiments conducted by US Army scientists, yet they were considered irrelevant to humans. Here we draw attention to that the underlying cause of hemoglobin-induced aggravation of hemorrhagic shock and severe HSRs have a common pathomechanism: cardiovascular distress due to vasoconstrictive effects of hemoglobin (Hb) and reactogenic nanomedicines, manifested, among others, in pulmonary hypertension. The main difference is that in the case of Hb this effect is due to NO-binding, while nanomedicines can trigger the release of proinflammatory mediators. Because of the higher sensitivity of cloven-hoof animals to this kind of cardiopulmonary
distress compared to rodents, these reactions can be better reproduced in pigs than in murine or rat models. When deciding on the battery of tests and the appropriate models to identify the potential hazard for nanomedicine-induced severe HSR, the pros and cons of the various species must be considered carefully.

Keywords: nanopharmaceuticals, hypersensitivity reactions, anaphylactic shock, hemorrhagic shock, trauma, porcine CARPA model, cardiopulmonary distress, pulmonary hypertension

INTRODUCTION

A frequent concern during the clinical development of novel nano-engineered drugs and biologicals is the possibility of unforeseen toxicities due to the unique physicochemical characteristics of particulate material in the nano (10⁶–10⁹ m) dimension. In particular, nanomedicines and biologicals are prone to cause hypersensitivity reactions (HSRs), also known as infusion reactions, which can be severe or even lethal. Examples of withdrawal from the United States or EU marketing, or suspension of an advanced clinical trial due to HSR-related severe adverse events (SAEs) include the PEGylated drugs Peginesatide (Omontys®) (1), Pegloticase (Krystexxa®) (2), Pegnivacogin (Revolixys®) (3) and iron-containing contrast agents Sinerem and Resovist (4, 5). Such unpredicted occurrence of HSR-related SAEs, even with drugs that pass all preclinical immune toxicity panels, reflects an important gap in nanotoxicology testing. This gap can be attributed, at least in part, to the lack of validated animal models for nanomedicine-induced HSRs (6). Although HSRs can be induced by reactogenic nanomedicines in many animal species, none of them reproduces the transient hemodynamic, hematological, cutaneous, and other physiological changes with the same sensitivity (i.e., minimal reactogenic dose in the μg/kg range) and occurrence rate (2–80%) as seen in humans (7–9).

One approach that aims to fill this gap is the “porcine complement (C) activation-related pseudoallergy” (CARPA) model, wherein all kinds of reactogenic nanoparticles (NPs) can induce anaphylactoid reactions that mimic many aspects of human HSRs both in their dose response, time course, and spectrum of symptoms (7, 10–15). The different NPs shown to be reactogenic in pigs include liposomal drugs (13, 14, 16), solid lipid NPs (SLNPs) (17), iron-oxide NPs (5, 18), and polymeric NPs (19, 20), all above with and without conjugation with polyethylene glycol (PEG) or other types of conjugates (21–24). In addition to NPs, the symptoms of CARPA can be induced in pigs by lipid emulsions (12) and PEGylated proteins or other conjugates of proteins (23). The unique advantage of the porcine model is that it not only identifies the risk of HSRs with clinically relevant sensitivity (25), but it also allows studying different approaches of avoiding the problem. For example, pig studies have identified some reaction-promoting physicochemical features of NPs, such as strong negative or positive surface charge, large size and inhomogeneity, or high cholesterol content of liposomes (26). It was in pig studies that the HSR-reducing effect of lenticular, faceted (27–29), rod-like or disk-shape (20) morphology of NPs versus their customary spherical design was described. Likewise, the pig model suggested the efficacy of pharmacological prevention of CARPA with C inhibitors, cyclooxygenase blockers (30) and desensitization with placebo vesicles (31). Slow infusion of NPs is a well-known empiric approach to prevent HSRs, and the pig model enabled to customize safe infusion protocols for specific nanomedicines, such as corticosteroid-containing liposomes (22). Perhaps the best industrial and regulatory proof of the model’s utility is the fact that the safe human administration protocol for double-stranded small interfering RNA (siRNA)-delivering SLNPs was developed in the pig model (17), Patisiran (Onpattro®) being the first federal drug administration (FDA)-approved gene therapy using (phospho)lipid-based nano-delivery vehicles (32).

Despite all these benefits, the pig model was recently challenged and not recommended for nanomedicine safety evaluation on the basis that it “excludes otherwise promising nanopharmaceuticals from the development pipeline on safety grounds that are not relevant to wider human populations” (6, 33). The authors of the latter publications claimed that the cardiopulmonary response of pigs to NPs represents a “global” phagocytic response, a feature of cloven-hoof animals due to the presence of pulmonary intravascular macrophages (PIMs) in their lung, making the pigs’ cardiopulmonary reaction “inappropriate and misleading” (6, 33), “scientifically questionable” (33) for safety testing.

It was recently pointed out (34) that the above claims fail to take into consideration that not all NPs induce HSRs in pigs and the reactions differ not only among different NPs (13), but even among chemically identical NPs with different shape (20), ruling out the claim of globality. It was also emphasized that the pig model is a disease model, i.e., that of hypersensitivity to nanomedicines, and not a standard toxicity model which uses healthy animals to assess toxic effects in the normal population. It is good for hazard identification, i.e., to predict or rule out a risk of HSR to the tested NPs, and if there is a risk, the model allows to mitigate it, as mentioned above. Use of the model may prevent major problems arising in late clinical trials or after marketing of the drug, thus its choice should be based on the benefit of early recognition of a potential problem that would otherwise stay undetected until late stages of a long and costly development process. In keeping with the above views, the primary author behind the criticism of the pig model (6, 33) did use the model to recommend a new strategy to mitigate the HSRs to polystyrene NPs in pigs (20).

The main goal of the present review is to add another angle to the debate over NP safety models by showing an example from the past, wherein disregard of pig studies turned out to be a detrimental mistake. We revive a clinical study sponsored by Baxter Healthcare in 1998, wherein treating of trauma patients...
with a hemoglobin (Hb)-based oxygen carrier (HBOC) blood substitute led to increased death relative to control, which outcome could have been predicted and prevented by considering experimental data obtained in pigs, using the same endpoints that are used in the porcine CARPA model for HSR prediction. As highlighted below, the reason of paralleling HBOC-induced aggravation of hemorrhagic shock and nanomedicine-induced (pseudo)anaphylactic shock lies in their common physiological root, i.e., vasoconstriction-related cardiopulmonary distress, for which pigs provide a uniquely sensitive model.

HEMOGLOBIN-BASED OXYGEN CARRIERS AND THE HISTORY OF FAILED CLINICAL TRIAL WITH DIASParkin-CROSS-LINKED HEMOGLOBIN

Hemoglobin-based oxygen carriers represent a unique class of engineered metalloproteins which have been developed since the late 1960s as universal plasma expander red blood cell substitutes (35, 36). Although HBOCs have traditionally not been considered as nanomedicines, the size of Hb (d: 5 nm) and engineered nature of HBOCs qualify them as a class of nanomedicine (37) with the peculiarity that their active ingredient is not a drug but a natural gas: O\textsubscript{2}. The diseases that HBOCs were intended to alleviate include general and/or local hypo- or anoxia – a universal cause of organ failure and death. Different illnesses leading to this life-threatening condition include traumatic blood loss, myocardial infarction, drowning, poisonings and various types of shock. Additionally, chronic forms of major \( \text{O}_2 \) deficit include certain respiratory and hematological diseases in their terminal stage. Accordingly, an efficient and safe \( \text{O}_2 \)-carrier blood substitute represents a long sought-after Holy Grail in human pharmacotherapy (36).

Table 1 lists the HBOC products that reached clinical trials. Most of them have been abandoned by now, the research and development (R&D) in this field has new directions (38, 39). Nevertheless, HBOC research contributed considerably to the understanding of many aspects of \( \text{O}_2 \) delivery and circulatory control. Most notably, the vasoactivity

| Company          | Product Name       | Modified Hb          | Indication                                  | Status                                                   |
|------------------|--------------------|----------------------|---------------------------------------------|----------------------------------------------------------|
| Baxter           | HemAssist (DCL-Hb)*| Diaspirin crosslinked-Hb | Hemorrhagic shock                           | In 1999 failed Phase III                                  |
| Biopure (later OPKbiotech, now HbO2 Therapeutics) | Hemopure (HBOC-201 and HBOC-301) | Polymerized bHb | Canine anemia, hemorrhagic shock             | HBOC-201 in expanded access clinical trials, approved in South Africa and Russia. Oxyglobin (HBOC-301) approved for veterinary use |
| Curacyte/Apex    | PHP/Hemoximer*     | PEG-hHb              | Shock with systemic inflammatory syndrome    | In 2014 failed Phase III due to increased mortality       |
| Enzon            | PEG-Hb*            | PEG-bHb              | To increase tumor oxygenation and enhance radiation and chemotherapy. | Phase I completed then development halted in 1998         |
| Hemarina         | M101               | Arenicola marina Hb  | Sickle cell anemia, hemorrhagic shock         | In preclinical development (Hemo2Life used for transplant organ preservation) |
| HemoBiotech      | Hemotech           | Polymerized/conj. bHb| Acute blood loss                             | Currently in or completed Phase I                        |
| Hemosol          | Hemolink*          | hHb oligomer         | Cardiothoracic surgery                       | Halted in 2003 after Phase II safety concerns, bankruptcy in 2005 |
| Northfield       | PolyHeme*          | Polymerized hHb      | Trauma, bleeding disorder                     | Completed Phase III in 2007. BLA failed in 2009 due to efficacy and adverse effects |
| Oxyvita Inc.     | OxyVita            | Zerolink bHb polymer | Traumatic brain injury, hemorrhage            | In preclinical development                               |
| Prolong          | Sanguinate         | PEG-bHb              | Sickle cell disease, vaso-occlusive crisis   | Phase II enrollment ended in 2017, under analysis         |
| Sangart          | Hemospan (MP4OX)*  | mPEG-hHb             | Hemorrhagic shock, limb ischemia             | Completed Phase II, b in 2012, Phase IIc withdrawn. Shut down in 2013 after $260M-plus R&D spending due to funding issues |
| Somatogen        | Optro*             | Recombinant Hb       | Cardiac surgery                              | In 2014 failed Phase II due to excessive vasoconstriction |
| Synzyme          | SanFlow (PNPH)     | Polynitroxylated PEG-Hb | Stroke, traumatic brain injury, hemorrhagic shock | In preclinical development                               |

*Terminated Development, h = human, b = bovine. Adapted and updated from (45).
of bis(3,5-dibromosalicyl)fumarate (diaspirin)-cross-linked Hb (DCLHb), also known as αα-cocrosslinked Hb (ααHb, HemAssist\textsuperscript{TM}) \((40, 41)\) has drawn much scientific and public attention because of the ill-fated clinical trial with this HBOC. It was the first blood substitute that reached Phase III clinical trials in trauma patients, sponsored by Baxter Healthcare Corporation (Illinois, USA) \((42)\). However, the study had to be abandoned prematurely as soon as it was recognized that treatment with HemAssist\textsuperscript{TM} significantly increased the risk of myocardial infarction and death relative to control patients receiving traditional treatments \((43)\). In particular, 24 of 52 patients given the blood substitute died compared to 8 of 46 in the control group \((43)\). The study also raised ethical concerns regarding informed consent \((43)\) and other regulatory issues, forcing Baxter to abandon its blood substitute program in 1998, after 13 years of R&D, costing more than half a billion dollars \((42)\).

The other HBOCs that reached Phase II or III clinical trials (Table 1) did not gain regulatory approval in the US, either, due to a common cause: increased risk of cardiovascular dysfunction and other adverse reactions without significant reduction in need for allogenic blood, or other major advantage over the contemporary standard of care \((44)\). Only Biopure Corporation’s (Cambridge, MA, United States) Oxyglobin\textsuperscript{R} was approved for use in canine anemia and Hemopure\textsuperscript{R} for human blood loss in South Africa and Russia, but these products also disappeared after the company’s bankruptcy in 2009.

The final hit on the field was a meta-analysis of mortality and myocardial infarction in 16 randomized controlled clinical trials involving surgical, stroke and trauma patients, treated between 1980 and 2008 with five different HBOCs (PolyHeme, HemeAssist, Hemolink, Hemopure and Hemospan), which came to the conclusion that HBOCs pose a 30% elevated risk of death and a nearly threefold greater risk of myocardial infarction compared to standard therapies \((46, 47)\). This information led the FDA in 2008 to put a hold on R&D of all HBOCs until solving the life-threatening adverse effects by improved formulations \((48–50)\).

As for the question, why were all these problems not foreseen despite extensive preclinical studies, the FDA/NIH workshop...
(48) referred, among others, to the fact that “conventional single
and repeated-dose safety and toxicity testing of the various
HBOCs in preclinical animal models have not been able to predict
the adverse outcomes frequently observed in clinical trials” (49,
50). However, in an “unconventional” toxicity model conducted
by US Army scientists in the early 1990s, wherein pigs were
pretreated to provide a model for battlefield hemorrhage, the
animals did show adverse physiological changes that offset the
benefits of acellular Hb and might have explained, at least in part,
the failure of clinical trials with HBOCs (44, 51–54). A thorough
analysis of these data led C. R. Winslow, in a contemporary
review, answer with “yes” to the question whether the failure of
clinical trials with HBOC could have been predicted in preclinical
studies (55).

The section below summarizes the pig data predicting the lack
of efficacy and increased risk for severe adverse effects of HBOCs
in patients losing blood.

**PIG STUDIES MODELING THE SERIOUS
ADVERSE EFFECTS OF HBOCS**

In order to study the efficacy and safety of ααHb, the HBOC
developed by US army scientist for battlefield indications,
a porcine model of controlled hemorrhage was developed
(44, 51–54, 56). The results of these studies indicated increased
systemic and pulmonary vascular resistance in HBOC-treated
pigs compared to crystalloid- or colloid-treated controls (Ringer’s
lactate, albumin, stroma-free HbA0), placing the animals’ hearts
on an “unfavorable portion of the Frank-Starling curve” (52).
Along with the hypertensive effects, the animals treated with
free Hb displayed reduced cardiac output and elevations of
plasma creatin kinase (CK), lactate dehydrogenase (LDH), and
creatinine, reflecting, among other cell damages, myocardial
necrosis and acute renal failure (51, 52). Taken together with the
immediate death and myocardial infarction in 2 of 14 pigs treated
with free Hb (51), these findings led Hess et al. to the conclusion
already in 1993 that the toxicities observed in pigs “raise concerns
over the clinical applications” of HBOCs (51).

Focusing on the main problem of using HBOCs after
hemorrhage, **Figure 1** illustrates the major hemodynamic
derangement after i.v. administration of ααHb versus control
solutions. The presented changes include significant rises
of systemic and pulmonary vascular resistance (SVR, PVR),
manifested in major rises of mean systemic and pulmonary
arterial blood pressures (MAP, SAP) and reduction of
cardiac output (CO).

The scheme in **Figure 2** illustrates the major processes
involved in the circulatory effects following acute blood loss
and HemAssist™ treatment, explaining the above hemodynamic

![Hemorrhage vs HemAssist](image-url)

**FIGURE 2** | Hypothetical scheme of adverse physiological effects of HemeAssist contributing to decreased survival after hemorrhage. Severe hemorrhage leads to increased sympathetic activation, resulting in vasoconstriction. The blood loss also causes decreased hematocrit, consequently lower viscosity, lower shear stress and lower NO production. NO in the blood, which would be responsible for keeping blood vessels open, is further reduced by the scavenging effect of the free plasma Hb of HemAssist™, worsening the vasoconstriction. Although treatment with HemAssist™ provides volume replacement and increased O₂ carrying capacity, which would lead to restoration of cardiac output, it is counteracted by the increased pulmonary vasoconstriction and consequent decrease of left ventricular preload, cardiac output, and diminished peripheral capillary blood flow, hindering tissue gas exchange. The scheme was modified from (42).
changes and consequent decreased survival. Among the causes, free plasma Hb in HemeAssist binds NO in blood, thereby contributing to vasoconstriction initially caused by the decreased viscosity and sympathetic activation due to hemorrhage. Besides decreasing capillary blood flow and tissue oxygenation, vasoconstriction in the lungs can lead to increased right ventricular afterload and reduced left ventricular preload, entailing myocardial ischemia, right ventricular failure and compromised cardiac output, all worsening the direct effects of blood loss.

Together with the coronary and peripheral vasoconstriction-related myocardial and other tissue hypoxia, these effects accelerate multiorgan failure, shock and death.

These findings in pigs provide reasonable explanation for the clinical outcome of the Baxter trial, while other studies also clarified that it was an intrinsic capability of free Hb to induce these effects, and they were not due to impurities in HBOCs. Nevertheless, the trial was justified and greenlit relying on animal data that showed improved tissue oxygenation and benefits from vasoconstriction. Chen et al. (36) counted 114 Pubmed-listed animal studies on HemAssist™, among which the pig studies showing ααHb to aggravate hemorrhagic shock were published well before the Baxter trial (54, 56, 57).

THE SIMILARITY BETWEEN HBOC-INDUCED AGGRAVATION OF HEMORRHAGIC SHOCK AND PORCINE CARPA

Figure 3 shows the changes of systemic (SAP) and pulmonary arterial pressure (PAP) caused by i.v. injection of PEGylated liposomes (Doxebo) in a pig that had been immunized with the same liposomes to raise the anti-PEG antibody level in blood. The animal displayed sudden rise of both PAP and SAP, the latter turning into hypotension and shock within 2 min, requiring resuscitation (21).

The highly reproducible finding in Figure 3 was shown to coincide with a significant increase of porcine sC5b-9 in blood and clearance of anti-PEG IgM, attesting to antibody-induced classical pathway complement (C) activation (21). Yet other studies indicated that i.v. injection of human C5a in pigs partially reproduced the above PAP and SAP changes (Figure 4) (58), and that liberation of thromboxane A₂ (TXA₂) is a rate-limiting step in HSRs (30). Taken together, these results clearly indicate the involvement of C activation and subsequent liberation of vasoactive mediators in the presented HSR, representing CARPA.

Figure 5 outlines the molecular and cellular interaction underlying the symptoms of CARPA, including C activation (by reactogenic liposomes), anaphylatoxin and TXA₂ liberations, consequent rises of SVR, PVR, SAP, and PAP due to vasoconstriction, and reduction of CO, i.e., very similar changes as seen in HBOC-induced tissue hypoxia and reduction of survival (Figures 1, 2). The main difference is that in the latter case vasoconstriction is mainly due to blocking of NO’s vasodilating effect, while in CARPA it is triggered by proinflammatory mediators, including anaphylatoxins and TXA₂ (Figures 2, 5).

Importantly with respect to aligning the effects of nanomedicines to those of HBOCs, the above severe hemodynamic derangement caused by minute amounts of reactogenic nanomedicines are observed in pigs, and supposedly in other cloven hoof animals, but not in rats or mice. Although rodents also react to certain iv. nanomedicines with hemodynamic changes, the effect is seen only at extremely high doses that are clinically not relevant (59–61). Thus, it
does not seem reasonable to replace the pig model with a rat or mouse model to mimic human HSRs, and the idea to use a cirrhotic rat model seems even more far-fetched (6). On the other hand, arguing against a model which can sensitively show these adverse effects (6, 33) diminishes the possibility of early identification of potential SAEs on grounds that can be fundamentally questioned (34).

THE TRANSLATIONAL VALUE OF THE PIG MODEL

Unpredicted immune and other toxicities by nanomedicines represent a well-recognized potential barrier to the clinical translation of this new class of pharmacotherapeutics (8, 9). One cause of this situation is a lack of animal toxicity models that would mimic rare SAEs due to HSRs. The substantial species-related and individual variations of immune responses to nanomedicines make modeling and predicting immune toxicities difficult, and particularly hard for rare HSRs. To predict such events in a model that mimics the prevalence of human HSR would require 100/X tests, where X is the incidence (expressed in%) of the HSR in man. However, this would not be feasible or practical, particularly at low% (X) values, i.e., a reaction that occurs once out of 1000 treatments would require 1000 experiments at the very least, without statistical power, to see 1 reaction. However, even a 1:1000 incidence of a severe or lethal HSR would be unfavorable for certain therapeutics.

FIGURE 4 | Cardiopulmonary and ECG changes caused by injection of recombinant human C5a. (A) Injection of 330 ng/kg rhuC5a. (B–D) Injection of 440 µg/kg rhC5a. (B) SAP. (C) PAP. (D) PCO2. Animal was resuscitated with epinephrine (B). Typical experiment out of three independent tests. Reproduced from (58) with permission.
The porcine CARPA test (7, 10–24) overcomes the problem of rare manifestation of NP-induced hypersensitivity in man inasmuch as pigs “outwardly reproduce” (6) the life-threatening symptoms of human HSRs to certain reactogenic NPs (e.g., liposomes) in essentially all pigs, without substantial individual variation. Because of this feature, the model is increasingly used both in academic and industrial R&D (34). However, as mentioned in the introduction, the model was vociferously opposed on the basis of a claim that the cardiopulmonary reaction of pigs represents a cloven-hoof-specific “global” phagocytic response by PIM cells to NPs, i.e., a uniform, non-specific and non-quantitative response (6, 33). These and other claims in (6, 33) were closely scrutinized and rejected in many aspects (34), however, an important role of PIM cell stimulation leading to HSRs in pigs has not been questioned (34).

Considering that the use of the pig model has been referred to as “porcine CARPA test”, a name implying the involvement of C activation, the question arises, what are the roles of C activation vs. PIM cells in the physiological changes observed in the model? Which is more important or rate limiting under different conditions, if any? An answer is suggested by the “double hit” theory (10, 13–15), claiming that HSRs arise when PIM cells (or corresponding macrophages) are simultaneously “hit” by at least two independent stimuli, one being anaphylatoxin binding to these cells as a consequence of C activation. Accordingly, the pulmonary reaction of pigs to different NPs were shown to be be partially mitigated at the level of C activation, by blockers of anaphylatoxin (C5a) action (30), and more effectively at the PIM cell level, by depleting (20) or blocking these cells’ secretion of vasoactive mediators (30). Nevertheless, it is a complex cascade of molecular and cellular interactions that link
C activation to PIM cell release reaction (Figure 6) (21), and C activation can induce pulmonary hypertension independent of PIMs [e.g., pulmonary leuko-thromboembolism (34)], just as PIM cells can release vasoactive mediators independent of C activation (C-independent pseudoallergy, CIPA). All these variations taken together, it cannot be generalized which step or event in the HSR cascade is rate limiting in man or different animals under different conditions. Thus, sole focus on PIM cells or other steps may not legitimize or discredit different models of HSRs.

The translational value of the pig model lies in the dominance of uniquely sensitive PIM cells in the HSR cascade, reducing the individual variation of innate cellular response to NPs in pigs, that may contribute to the rarity of hypersensitivity symptoms in man. Although it is not known at this time whether hypersensitivity in man is due to increased cellular and/or humoral innate immune response, or at another step in the scheme, the identity of cardiopulmonary symptoms and sensitivity to NPs of hypersensitive man and pigs give rise to speculations that the amplification of C signal is due to the presence of hypersensitive secretory macrophages in the lung of reactive patients, just like PIMs in pigs. The high sensitivity of the pig model ensures that the chance of false negative results are minimized, providing a high negative predictive value (the probability that test NPs with a negative screening test truly don’t provoke the reaction), which is desirable if the goal is to rule out the potential for SAEs in future advanced trials.

It should also be added that adverse events in a preclinical animal model do not necessarily exclude the success of the tested drug in man, they just draw attention to the risk, which can be addressed and controlled. In the case of HBOCs, if the studies on hemorrhaged pigs, representing a controlled model of traumatic blood loss (44, 51–54, 56), had been given more attention, and the observations used to develop preventive measures validated in early investigational human experiments, the model could have saved not only the life of many patients but also the R&D of HBOCs. It is difficult to reconstitute why all these did not happen. Chen et al. noted that there was a disagreement between researchers at Baxter Healthcare and the US Army regarding the direction of ααHb R&D, and the two groups severed ties (36).

**WARNING AGAINST THE WARNING**

Hopefully, history will not repeat itself and attempts to discredit the pig model (6, 33) will not expose patients to increased risk for HSRs in premature, ill-designed clinical studies. In our view, it is the argument that we should disregard concerns about safety raised in the pig model, that is “inappropriate, misleading and scientifically questionable”, i.e., the terms used for the pig model
CONCLUSION

The present review adds further support to the use of the pig model by providing an example from the past when failure to consider data obtained in pigs led not only to the demise of a drug candidate but also the stunted progress of a whole field of research. Drawing analogy between HBOC’s hemodynamic effects aggravating hemorrhagic shock in trauma patients and nanomedicine-induced CARPA leading to (pseudo)anaphylactic shock is justified by the similarities in the pathophysiological mechanism of the two phenomena. The example of HemAssist may be particularly educational for those in the position of deciding on the use of animal models for solving various problems, such as a risk for nanomedicine-induced severe HSRs. Once again, pigs may turn out to be not only useful but critical one. A body of preclinical data and expert opinions, free from financial conflict of interests or intellectual biases, is critical to help informed, more nuanced judgments. Nevertheless, beside addressing and clarifying the claims that we found incorrect in the reviews by Moghimi et al. (6, 33), we acknowledged the benefits of professional disputes, as they extend understanding and may resolve unclear issues in the field (34).

REFERENCES

1. Weinhandl ED, Gilbertson DT, Collins AJ, Foley RN. Relative safety of peginesatide and epoetin alfa. *Pharmacoepidemiol Drug Saf.* (2014) 23:1003–11. doi: 10.1002/pds.3655
2. Calabrese LH, Kavanaugh A, Yeo AE, Lipsky PE. Frequency, distribution and immunologic nature of infusion reactions in subjects receiving pegloticase for chronic refractory gout. *Arthritis Res Ther.* (2017) 19:191.
3. Povsic TJ, Vavalle JP, Aberle LH, Kasprzak JD, Cohen MG, Mehran R, et al. A Phase 2, randomized, partially blinded, active-controlled study assessing the efficacy and safety of variable anticoagulation reversal using the REG1 system in patients with acute coronary syndromes: results of the RADAR trial. *Eur Heart J.* (2013) 34:2481–9. doi: 10.1093/eurheartj/ehs232
4. Wang YX, Idee JM. A comprehensive literatures update of clinical researches of superparamagnetic resonance iron oxide nanoparticles for magnetic resonance imaging. *Quant Imaging Med Surg.* (2017) 7:88–122. doi: 10.21037/qims.2017.02.09
5. Fulop T, Nemes R, Meszaros T, Urbanics R, Kok RJ, Jackman JA, et al. Complement activation in vitro and reactivity of low-molecular weight dextran-coated SPIONs in the pig CARPA model: correlation with physicochemical features and clinical information. *J Control Release.* (2018) 270:268–74. doi: 10.1016/j.jconrel.2017.11.043
6. Moghim SM, Simberg D. Translational gaps in animal models of human infusion reactions to nanomedicines. *Nanomedicine (Lond).* (2018) 13:973–5. doi: 10.2217/nmm-2018-0064
7. Szebeni J, Alving CR, Rosivall L, Burger R, Baranyi L, Bedocs P, et al. Animal models of complement-mediated hypersensitivity reactions to liposomes and other lipid-based nanoparticles. *J Liposome Res.* (2007) 17:107–17. doi: 10.1080/08982100701375118
8. Zamboni WC, Szebeni J, Kozlov SV, Lucas AT, Piscitelli JA, Dobrovolskaia MA. Animal models for analysis of immunological responses to nanomaterials: challenges and considerations. *Adv Drug Deliv Rev.* (2018) 136–137:82–96. doi: 10.1016/j.addr.2018.09.012
9. Szebeni J, Simberg D, Gonzalez-Fernandez A, Barenholz Y, Dobrovolskaia MA. Roadmap and strategy for overcoming infusion reactions to nanomedicines. *Nat Nanotechnol.* (2018) 13:1100–8. doi: 10.1038/s4156-018-0273-1
10. Szebeni J, Bedocs P, Csukas D, Rosivall L, Burger R, Urbanics RA. Porcine model of complement-mediated infusion reactions to drug carrier nanosystems and other medicines. *Adv Drug Deliv Rev.* (2012) 64:1706–16. doi: 10.1016/j.addr.2012.07.005
11. Szebeni J, Bedocs P, Rosznay Z, Weiszhar Z, Urbanics R, Rosivall L, et al. Liposome-induced complement activation and related cardiopulmonary distress in pigs: factors promoting reactogenicity of Doxil and Ambisome. *Nanomedicine.* (2012) 8:176–84. doi: 10.1016/j.nano.2011.06.003
12. Bedocs P, Capaccione J, Potts L, Chugani R, Weiszhar Z, Szebeni J, et al. Hypersensitivity reactions to intravenous lipid emulsion in swine: relevance for lipid resuscitation studies. *Anesth Analg.* (2014) 119:1094–101. doi: 10.1213/ane.0000000000003996
13. Urbanics R, Szebeni J. Lessons learned from the porcine CARPA model: constant and variable responses to different nanomedicines and administration protocols. *Eur J Nanomed.* (2015) 7:219–31.
14. Szebeni J, Bedocs P, Dézsi L, Urbanics R. A porcine model of complement activation-related pseudoallergy to nano-pharmaceuticals: pros and cons of translation to a preclinical safety test. *Prec Nanomed.* (2018) 1:63–73. doi: 10.29061/1804271
15. Szebeni J. Mechanism of nanoparticle-induced hypersensitivity in pigs: complement or not complement? *Drug Discov Today.* (2018) 23:487–92. doi: 10.1016/j.drudis.2018.01.025
16. Szebeni J, Muggia F, Galbizon A, Barenholz Y. Activation of complement by therapeutic liposomes and other lipid excipient-based therapeutic products: prediction and prevention. *Adv Drug Deliv Rev.* (2011) 63:1020–30. doi: 10.1016/j.addr.2011.06.017
17. Kasperovic P. Dosages and Methods for Delivering Lipid Formulated Nucleic Acid Molecules. US patent application #20160122759. (2016). doi: 10.1016/j.addr.2011.06.017
33. Moghimi SM, Simberg D, Skotland T, Yaghmur A, Hunter C. The interplay of Nanomedicines. Drugs. (2018) 78:1625–31. doi: 10.1007/100405-018-0983-6
34. Szebeni J, Bawa R. Human clinical relevance of the porcine model of pseudoleukemic infusion reactions. Biomedicine. (2020) 8:82. doi: 10.3390/biomedicides8040802
35. Winslow RM. Red cell substitutes. Semin Hematol. (2007) 44:51–9.
36. Chen JY, Sceibo M, Kramer G. A review of blood substitutes: examining the history, clinical trial results, and ethics of hemoglobin-based oxygen carriers. Clinics (São Paulo). (2009) 64:803–13.
37. Bawa R, Johnson S. Emerging issues in nanomedicine and ethics. In: Alhoff F, Lin P editors. Nanoethics: Emerging Debates. Dordrecht: Springer (2008).
38. Alayash AI. Hemoglobin-based blood substitutes and the treatment of sickle cell disease: more harm than help? Biomolecules. (2017) 7:2. doi: 10.3390/biom7010002
39. Khan F, Singh K, Friedman MT. Artificial blood: the history and current perspectives of blood substitutes. Discoveries (Crawley). (2020) 8:e104.
40. Nelson D, Azari M, Brown R, Burchop K, Bush S, Catarrello J, et al. Preparation and characterization of diaspiprin cross-linked hemoglobin solutions for preclinical studies. Biomater Art Cell Immobilization Biotechnol. (1992) 20:423–7. doi: 10.1016/073299169662
41. Nelson D, Hai T, Srnak A, Ebeling A, Kunas C, Catarrello J, et al. Synthesis and properties of polymerized, diaspiprin cross-linked hemoglobins. Biomater Art Cell Immobilization Biotechnol. (1992) 20:253–8. doi: 10.1016/0732-9916(94)00016-
42. Winslow RM. Alpha-alpha-crosslinked hemoglobin: was failure predicted by preclinical testing? Vox Sang. (2000) 79:1–20. doi: 10.1111/0005-376X.001220
43. Sloan EP, Koenigsberg M, Lens D, Cipolle M, Runge, J, Mallory MN, et al. Diaspiprin cross-linked hemoglobin (DCLHB) in the treatment of severe traumatic hemorrhagic shock: a randomized controlled efficacy trial. JAMA. (1999) 282:1857–64. doi: 10.1001/jama.282.19.1857
44. de Figueredo LF, Mathur M, Solanki D, Macdonald VW, Hess J, Kramer GC. Pulmonary hypertension and systemic vasconstriction may offset the benefits of acellular hemoglobin blood substitutes. J Trauma Acute Care Surg. (1997) 42:847–54. doi: 10.1097/00005373-199705000-00015
45. Sair J, Sadighi A, Doherty LL, Li A, Kim HW. Hemoglobin-based oxygen carriers: history, limits, brief summary of the state of the art, including clinical trials. In: Mozzarelli A, Bettati S editors. Chemistry and Biochemistry of Oxygen Therapeutics: From Transfusion to Artificial Blood. Chichester: John Wiley and Sons, Ltd (2011). p. 301–16.
46. Natanson C, Kern SJ, Lurie P, Banks SM, Wolfe SM. Cell-free hemoglobin-based blood substitutes and risk of myocardial infarction and death: a meta-analysis. JAMA. (2008) 299:2304–12. doi: 10.1001/jama.299.19.jr00007
47. Schmidt C. Meta-analysis torpedoes blood substitutes. Nat Biotechnol. (2008) 26:721–3. doi: 10.1038/nbt0708-721a
48. FDA/NIC Hemoglobin-based Oxygen Carriers: Current Status and Future Directions. Bethesda, MD: FDA/NIC (2008). doi: 10.1038/nbt0708-721a
49. Silverman TA, Wesskopf RB. Hemoglobin-based oxygen carriers: current status and future directions. Transfusion. (2009) 49:2495–515. doi: 10.1111/j.1537-2995.2009.02356.x
50. Silverman TA, Wesskopf RB, Planning Committee and the Speakers Hemoglobin-based oxygen carriers: current status and future directions. Anesthesiology. (2009) 111:946–63.
51. Hess J, Macdonald VW, Brinkley WW. Systemic and pulmonary hypertension after resuscitation with cell-free hemoglobin. J Appl Physiol (1985). (1993) 74:1769–78. doi: 10.1152/jappl.1993.74.4.1769
52. Hess J, Macdonald VW, Gomme GS, Copps V. Increased vascular resistance with hemoglobin-based oxygen carriers. Artif Cells Blood Substit Immobil Biotechnol. (1994) 22:361–72.
53. Hess J. Review of modified hemoglobin research at Letterman: attempts to delineate the toxicity of cell-free tetrameric hemoglobin. Artif Cells Blood Substit Immobil Biotechnol. (1995) 23:277–89. doi: 10.3109/1073119950917944
54. Hess JR, Reiss RF. Resuscitation and the limited utility of the present generation of blood substitutes. Transfus Med Rev. (1996) 10:276–85. doi: 10.1016/1087-7963(96)00034-0
55. Winslow RM. Current status of oxygen carriers (‘blood substitutes’). Vox Sang. (2006) 91:102–10. doi: 10.1111/j.1423-0410.2006.00789.x
56. Hess JR, Macdonald VW, Winslow RM. Dehydration and shock: an animal model of hemorraghe and resuscitation of battlefield injury. Biomater...
57. Hess JR, Wade CE, Winslow RM. Filtration-assisted exchange transfusion using alpha alpha Hb, an erythrocyte substitute. *J Appl Physiol* (1985). (1991) 70:1639–44. doi: 10.1152/jappl.1991.70.4.1639

58. Szebeni J, Baranyi L, Savay S, Bodo M, Milosevits J, Alving CR, et al. Complement activation-related cardiac anaphylaxis in pigs: role of C5a anaphylatoxin and adenosine in liposome-induced abnormalities in ECG and heart function. *Am J Physiol Heart Circ Physiol*. (2006) 290: H1050–8.

59. Dezsi L, Fulop T, Meszaros T, Szenasi G, Urbanics R, Vazsonyi C, et al. Features of complement activation-related pseudoallergy to liposomes with different surface charge and PEGylation: comparison of the porcine and rat responses. *J Control Release*. (2014) 195:2–10. doi: 10.1016/j.jconrel.2014.08.009

60. Orfi E, Meszaros T, Hennies M, Fulop T, Dezsi L, Nardocci A, et al. Acute physiological changes caused by complement activators and amphotericin B-containing liposomes in mice. *Int J Nanomedicine*. (2019) 14:1563–73. doi: 10.2147/ijn.s187139

61. Dezsi L, Meszaros T, Orfi E, Fulop TG, Hennies M, Rosivall L, et al. Complement activation-related pathophysiological changes in anesthetized rats: activator-dependent variations of symptoms and mediators of pseudoallergy. *Molecules*. (2019) 24:3283. doi: 10.3390/molecules24183283

**Disclaimer:** The opinions and assertions expressed herein are those of the author(s) and do not necessarily reflect the official policy or position of the Uniformed Services University, the Henry M Jackson Foundation, or the Department of Defense.

**Conflict of Interest:** JS is affiliated with SeroScience Ltd., a contract research SME providing immune toxicology services.

The remaining author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

*Copyright © 2020 Bedőcs and Szebeni. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.*